OnKure Announces $150M Private Placement and Board Changes

The latest announcement is out from OnKure Therapeutics ( (OKUR) ).

On March 27, 2026, OnKure Therapeutics entered into a $150 million private placement with institutional investors to sell 26,713,636 shares of Class A common stock at $4.15 per share and pre-funded warrants for 9,430,959 additional shares, with closing expected on March 31, 2026. The company plans to use the net proceeds to advance preclinical and clinical development of its next-generation PI3Kα pan-mutant-selective inhibitor candidates OKI-345 and OKI-355 in breast cancer and vascular anomalies, and for working capital and general corporate purposes.

In connection with the financing, OnKure granted lead investor AI Biotechnology LLC customary rights, including a board seat filled by Dr. Liam Ratcliffe as a Class I director upon closing, and agreed to lock-up and issuance restrictions for 180 days after closing and until the effectiveness of a resale registration statement. The company and investors also entered into a registration rights agreement requiring OnKure to register the resale of the new shares and warrant shares, while the pre-funded warrants are immediately exercisable at a nominal price but subject to beneficial ownership caps.

OnKure reported that its PIKture-01 Phase 1a/1b trial of PI3Kα inhibitor OKI-219 in HR+ and HER2+ advanced breast cancer had, as of March 26, 2026, completed enrollment in single-agent and fulvestrant combination dose-escalation cohorts, with Phase 2 dose evaluations of triple combinations planned to complete in 2026. However, given progress in its PI3Kα pan-mutant programs, the company does not plan to pursue further independent clinical development of OKI-219 and aims to present mature PIKture-01 data by year-end while targeting IND submissions for OKI-345 and OKI-355 in the first half of 2027.

The most recent analyst rating on (OKUR) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on OnKure Therapeutics stock, see the OKUR Stock Forecast page.

Spark’s Take on OKUR Stock

According to Spark, TipRanks’ AI Analyst, OKUR is a Neutral.

OKUR’s score is held down primarily by weak fundamentals (no revenue, widening losses, and heavy ongoing cash burn implying continued funding dependence). Technical momentum is a meaningful positive, with price trading above key moving averages and positive MACD, but valuation support is limited given negative earnings and no dividend data.

To see Spark’s full report on OKUR stock, click here.

More about OnKure Therapeutics

OnKure Therapeutics, Inc. is a biotechnology company focused on developing next-generation targeted oncology therapies, including PI3Kα pan-mutant-selective inhibitors for breast cancer and vascular anomalies. Its pipeline is designed to selectively inhibit mutant PI3Kα while sparing wildtype, aiming to deliver deeper, more durable responses with fewer class-limiting toxicities in combination and monotherapy settings.

Average Trading Volume: 254,894

Technical Sentiment Signal: Hold

Current Market Cap: $54.56M

For a thorough assessment of OKUR stock, go to TipRanks’ Stock Analysis page.